Loading...
Market
What strategic business move will Soleno make following FDA review by June 30, 2025?
2
Resolution / Starting Odds
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Press releases from Soleno Therapeutics or major financial news outlets
Story
Soleno Therapeutics' Prader-Willi Drug Gets Positive FDA Update, Stock Soars 12% to 52-Week High
Oct 8, 2024, 06:14 PM
Soleno Therapeutics has announced a regulatory update on its DCCR (diazoxide choline) extended-release tablets designed to treat Prader-Willi Syndrome. The FDA has decided not to require an advisory committee meeting for the drug, which is seen as a positive indication of the drug's potential approval. This decision has led to a 12% increase in Soleno's stock price, reaching a new 52-week high, with a 7.9% pre-market rise. The company has also received Priority Review for the drug candidate, further boosting investor confidence. Soleno's low cash burn and the potential for a short squeeze are additional factors contributing to the stock's rise. The FDA's decision highlights the unmet need for treatments addressing PWS-associated hyperphagia.
View original story
Similar markets
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Request for More Data • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Significant Increase (>20%) • 25%
Moderate Increase (10-20%) • 25%
No Significant Change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Approval recommended • 25%
Approval not recommended • 25%
No consensus • 25%
Meeting postponed • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%